OPTIMISE-AR:早期剂量探索肿瘤试验中患者报告结局分析与可视化的实用工具包推荐
OPTIMISE-AR 是由国际多学科跨部门统计分析与数据可视化工作组制定的政策综述,针对剂量探索肿瘤试验(DFOT)中患者报告结局(PRO)数据分析和报告不一致的问题,建立了围绕四个方法学领域的实用工具包,提供统计分析和数据可视化推荐,以支持稳健、以患者为中心的耐受性结论。
要点
- PRO 在剂量探索肿瘤试验的耐受性评估中作用日益增加,但分析与报告常不清晰且不一致。
- OPTIMISE-AR 工具包围绕四个方法学领域提供统计分析与可视化推荐。
- 推荐涵盖二分类、有序和连续 PRO 数据的分析,以评估跨剂量和时间点的耐受性。
核心结论
- OPTIMISE-AR 工具包促进 PRO 数据的分析与可视化,有助于得出稳健、以患者为中心的耐受性结论,并支持更广泛地开发可耐受且有效的治疗。
研究设计与样本
- 国际、多学科、跨部门的统计分析与数据可视化工作组识别了 PRO 数据的分析与可视化方法,以解决关键的 DFOT PRO 研究目标。
主要发现
- 本政策综述基于现有文献提供了案例研究和推荐,用于分析二分类、有序和连续 PRO 数据,以评估跨剂量和时间点的耐受性,并将 PRO 整合到中期和最终剂量决策过程中。
关键数值与推荐
- OPTIMISE-AR 工具包围绕四个方法学领域构建,与关键 DFOT PRO 研究目标一致,提供统计分析和数据可视化推荐:(1)跨时间点的 PRO 终点,(2)时间点之间的 PRO 终点,(3)时间至事件 PRO 终点,(4)基于模型剂量探索设计中用于正式剂量决策的 PRO 终点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patient-reported outcomes (PROs) are increasingly recognised for their role in assessing tolerability in dose-finding oncology trials (DFOTs). However, analysis and reporting of PRO data within DFOTs are often unclear and inconsistent. OPTIMISE-AR (Incorporating Patient-Reported Outcomes in Dose-Finding Trials-Analysis Recommendations) establishes a practical toolkit supporting the statistical analysis, visualisation, and reporting of PRO data within DFOT publications. International, multidisciplinary, cross-sector statistical analysis and data visualisation working groups identified analytical and visualisation approaches for PROs data, addressing key DFOT PRO research objectives. Informed by existing literature, case studies and recommendations are provided in this Policy Review for analysing binary, ordinal, and continuous PRO data to assess tolerability across doses and timepoints, and to integrate PROs into interim and final dose-decision processes. The OPTIMISE-AR toolkit is structured around four methodological domains aligned with key DFOT PRO research objectives, providing statistical analysis and data visualisation recommendations for (1) PRO endpoints across timepoints, (2) PRO endpoints between timepoints, (3) time-to-event PRO endpoints, and (4) PRO endpoints for formal dose-decision making in model-based dose-finding designs. As PROs have an increasing role in tolerability assessment, this Policy Review promotes analysis and data visualisation of PRO data, facilitating robust, patient-centred tolerability conclusions and supporting the broader development of tolerable and effective treatments.
引用
- Alger E, Regnault A, Dueck AC, et al. A practical toolkit with recommendations for analysing and visualising patient-reported outcomes in early phase dose-finding oncology trials (OPTIMISE-AR). Lancet Oncol. 2026. PMID: 41861833. doi:10.1016/S1470-2045(26)00018-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。